Literature DB >> 23784134

Susceptibility breakpoint for enrofloxacin against swine Salmonella spp.

Haihong Hao1, Huafang Pan, Ijaz Ahmad, Guyue Cheng, Yulian Wang, Menghong Dai, Yanfei Tao, Dongmei Chen, Dapeng Peng, Zhenli Liu, Lingli Huang, Zonghui Yuan.   

Abstract

Susceptibility breakpoints are crucial for prudent use of antimicrobials. This study has developed the first susceptibility breakpoint (MIC ≤ 0.25 μg/ml) for enrofloxacin against swine Salmonella spp. based on wild-type cutoff (COWT) and pharmacokinetic-pharmacodynamic (PK-PD) cutoff (COPD) values, consequently providing a criterion for susceptibility testing and clinical usage of enrofloxacin.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23784134      PMCID： PMC3754624          DOI： 10.1128/JCM.01096-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Simultaneous determination of fluoroquinolones in foods of animal origin by a high performance liquid chromatography and a liquid chromatography tandem mass spectrometry with accelerated solvent extraction.

Authors:  Huan Yu; Yanfei Tao; Dongmei Chen; Yuanhu Pan; Zhenli Liu; Yulian Wang; Lingli Huang; Menghong Dai; Dapeng Peng; Xu Wang; Zonghui Yuan
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-12-23       Impact factor: 3.205

Review 2.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

3.  Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations after intramuscular administration in healthy pigs.

Authors:  M Bimazubute; C Cambier; K Baert; S Vanbelle; P Chiap; A Albert; J P Delporte; P Gustin
Journal:  J Vet Pharmacol Ther       Date:  2010-04       Impact factor: 1.786

4.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

5.  Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.

Authors:  José Antonio Lepe; Emilio García-Cabrera; María Victoria Gil-Navarro; Javier Aznar
Journal:  Rev Esp Quimioter       Date:  2012-06       Impact factor: 1.553

6.  Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs.

Authors:  K M Messenger; M G Papich; A T Blikslager
Journal:  J Vet Pharmacol Ther       Date:  2011-09-14       Impact factor: 1.786

7.  Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs.

Authors:  A Anadón; M R Martínez-Larrañaga; M J Díaz; M L Fernández-Cruz; M A Martínez; M T Frejo; M Martínez; J Iturbe; M Tafur
Journal:  Am J Vet Res       Date:  1999-11       Impact factor: 1.156

Review 8.  Application of fluoroquinolone pharmacodynamics.

Authors:  D H Wright; G H Brown; M L Peterson; J C Rotschafer
Journal:  J Antimicrob Chemother       Date:  2000-11       Impact factor: 5.790

9.  Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.

Authors:  C Andrew DeRyke; Joseph L Kuti; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2007-03-09       Impact factor: 2.803

10.  Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

Authors:  M A Pfaller; D J Diekema; M A Ghannoum; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; A Espinel-Ingroff; C L Fowler; E M Johnson; C C Knapp; M R Motyl; L Ostrosky-Zeichner; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948
View more
  3 in total

1.  Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion.

Authors:  Kaixiang Zhou; Meixia Huo; Wenjin Ma; Kun Mi; Xiangyue Xu; Samah Attia Algharib; Shuyu Xie; Lingli Huang
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

2.  Susceptibility breakpoint for Danofloxacin against swine Escherichia coli.

Authors:  Yuqi Yang; Yixin Zhang; Jiarui Li; Ping Cheng; Tianshi Xiao; Ishfaq Muhammad; Hongxiao Yu; Ruimeng Liu; Xiuying Zhang
Journal:  BMC Vet Res       Date:  2019-02-04       Impact factor: 2.741

3.  Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study.

Authors:  Anxiong Huang; Xun Luo; Zihui Xu; Lingli Huang; Xu Wang; Shuyu Xie; Yuanhu Pan; Shiwei Fang; Zhenli Liu; Zonghui Yuan; Haihong Hao
Journal:  Front Pharmacol       Date:  2022-02-24       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.